Business Alignment vs Zhonghong Pulin Medical Products: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Business Alignment Public Company Limited (BIZ.BK)

Q3 202623 Jul – 8 Oct 2026

▲4

BIZ profit jumps, BIZGENES launch and Forbes nod lift growth story

Q2 profit surge and double-digit growth target BIZ's second-quarter 2026 net profit jumped 87.75% to 85.18 million baht and revenue rose 29.51%, with management keeping its double-digit full-year growth target. Strong earnings and a 1.259 billion baht backlog give investors confidence in future revenue, pushing the stock up.
The profit surge and maintained growth target are the core new financial results driving the stock.
BIZGENES launch opens new longevity market BIZ launched BIZGENES, a Thai DNA testing and precision health brand, to capture the healthy-longevity trend. It is expanding marketing and service channels across hospitals, clinics and consumers. This new business line adds future revenue and supports the growth story, lifting the stock.
The BIZGENES brand launch is a new growth driver that expands BIZ's addressable market.
Forbes Asia recognition boosts credibility BIZ was named to Forbes Asia's Best Under A Billion list for 2026, one of 18 Thai companies selected. Such recognition raises the company's profile with investors and can attract new buyers, supporting demand for the shares.
The Forbes award is a new external validation that can improve investor sentiment and visibility.
Strong governance score and new project bidding BIZ scored a perfect 100 on the 2026 AGM Checklist for the third straight year, signaling good governance. It is also bidding for government and medical school projects and aims for 200 million baht in recurring after-sales revenue within 2-3 years, supporting future earnings.
The governance score and bidding activity are new positive factors that reinforce the growth outlook.

August 202623 Jul – 8 Oct 2026

▲4

BIZ profit jumps, BIZGENES launch and Forbes nod lift growth story

Q2 profit surge and double-digit growth target BIZ's second-quarter 2026 net profit jumped 87.75% to 85.18 million baht and revenue rose 29.51%, with management keeping its double-digit full-year growth target. Strong earnings and a 1.259 billion baht backlog give investors confidence in future revenue, pushing the stock up.
The profit surge and maintained growth target are the core new financial results driving the stock.
BIZGENES launch opens new longevity market BIZ launched BIZGENES, a Thai DNA testing and precision health brand, to capture the healthy-longevity trend. It is expanding marketing and service channels across hospitals, clinics and consumers. This new business line adds future revenue and supports the growth story, lifting the stock.
The BIZGENES brand launch is a new growth driver that expands BIZ's addressable market.
Forbes Asia recognition boosts credibility BIZ was named to Forbes Asia's Best Under A Billion list for 2026, one of 18 Thai companies selected. Such recognition raises the company's profile with investors and can attract new buyers, supporting demand for the shares.
The Forbes award is a new external validation that can improve investor sentiment and visibility.
Strong governance score and new project bidding BIZ scored a perfect 100 on the 2026 AGM Checklist for the third straight year, signaling good governance. It is also bidding for government and medical school projects and aims for 200 million baht in recurring after-sales revenue within 2-3 years, supporting future earnings.
The governance score and bidding activity are new positive factors that reinforce the growth outlook.

Latest23 Jul – 8 Oct 2026

▲4

BIZ profit jumps, BIZGENES launch and Forbes nod lift growth story

Q2 profit surge and double-digit growth target BIZ's second-quarter 2026 net profit jumped 87.75% to 85.18 million baht and revenue rose 29.51%, with management keeping its double-digit full-year growth target. Strong earnings and a 1.259 billion baht backlog give investors confidence in future revenue, pushing the stock up.
The profit surge and maintained growth target are the core new financial results driving the stock.
BIZGENES launch opens new longevity market BIZ launched BIZGENES, a Thai DNA testing and precision health brand, to capture the healthy-longevity trend. It is expanding marketing and service channels across hospitals, clinics and consumers. This new business line adds future revenue and supports the growth story, lifting the stock.
The BIZGENES brand launch is a new growth driver that expands BIZ's addressable market.
Forbes Asia recognition boosts credibility BIZ was named to Forbes Asia's Best Under A Billion list for 2026, one of 18 Thai companies selected. Such recognition raises the company's profile with investors and can attract new buyers, supporting demand for the shares.
The Forbes award is a new external validation that can improve investor sentiment and visibility.
Strong governance score and new project bidding BIZ scored a perfect 100 on the 2026 AGM Checklist for the third straight year, signaling good governance. It is also bidding for government and medical school projects and aims for 200 million baht in recurring after-sales revenue within 2-3 years, supporting future earnings.
The governance score and bidding activity are new positive factors that reinforce the growth outlook.

Zhonghong Pulin Medical Products Co. Ltd. (300981.CS)

Q3 202628 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.

August 202628 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.

Latest28 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.